Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer

Lung Cancer

Volumn 36, Issue 1, 2002, Pages 71-76

  Sasaki, Hidefumi ^a   Tanahashi, Masayuki ^a   Yukiue, Haruhiro ^a   Moiriyama, Satoru ^a   Kobayashi, Yoshihiro ^a   Nakashima, Yoshiaki ^a   Kaji, Masahiro ^a   Kiriyama, Masanobu ^a   Fukai, Ichiro ^a   Yamakawa, Yosuke ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

LightCycler; Lung cancer; PPAR ; Prognosis

Indexed keywords

MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 0036123548     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00449-4     Document Type: Article

References (27)

1. Cancer of the lung
2. On behalf of the Japanese association for thoracic surgery: Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese association for thoracic surgery
3. On behalf of the lung cancer cooperative group of the EORTC: The experience of the lung cancer cooperative group of the European Organization for Research and Treatment of Cancer
4. Apoptosis: Its significance in cancer and cancer therapy
5. Apoptosis: Its role in the progression of and chemotherapy for carcinoma
6. PPARγ. Adipogenic regulator and thiazolidinedine receptor
7. Terminal differentiation of human breast cancer through PPARγ
8. Differentiation and reversal of malignant changes in colon cancer through PPARγ
9. A human perioxisome proliferator-activated receptor γ is activated by inducers of adipogenesis including thiazolidinedine drugs
10. Ligands for perioxisome proliferator-activator receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
11. Perioxisome proliferator-activated receptor γ1 expression is induced during cyclic adenosine monophosphate-stimulated differentiatio of alveolar typeII pneumonocytes
12. Perioxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells
13. Induction of differentiation and apoptosis by ligand of perioxisome proliferator-activated receptor γ in non-small cell lung cancer
14. The LightCycler: A microvplume multisample fluorimeter with rapid temperature control
15. Induction of solid tumor differentiation by the perioxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma
16. Ligand for perioxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
17. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the perioxisome proliferator-activated γ ligand, 15-deoxy-12, 14-prostaglandin J2
18. Troglitazone increases the number of small adipocyte without the change of white adipose tissue mass in obese Zucker rats
19. Inhibition of human lung cancer cell growth by th peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis
20. Matrix metalloproteinase degradation of elastin, type IV collagen, and proteoglycan: A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysin-1 and -2 and punctuatedmetalloproteinase (PUMP)
21. MMP-2: Expression, activation, and inhibition
22. Phase I trial of Marrimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
23. Disruption of epithelial-matrix interactions induces apoptosis
24. Cancer cell cycles
25. Prognostic significance of CCND1 (cyclinD1) overexpression in primary resected non-small cell lung cancer
26. Over-expression of cyclinD1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development